Operator
Good day, and thank you for standing by. Welcome to the Vivoryon Therapeutics 2025 Third Quarter Earnings Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the conference over to your first speaker today, Julia Neugebauer, COO. Please go ahead.
Julia Neugebauer
Chief Operating Officer & Executive Board Member
Thank you, [ Razia ]. Good morning or good afternoon, everyone, and thank you for joining us today for Vivoryon’s Third Quarter 2025 Results Call. Earlier today, we issued a press release reporting our third quarter 2025 financial results and business update, which can be found on Vivoryon’s website at www.vivoryon.com. On the call with me today are Frank Weber, our Chief Executive Officer; Marcus Irsfeld, our acting Chief Financial Officer; as well as Michael Schaeffer, our Chief Business Officer.
Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward-looking statements concerning the development of Vivoryon’s core platform, the progress of its current research and development programs and the initiation of additional programs as well as results of operations, cash needs, financial conditions, liquidity, prospects, future transactions and strategies. Should actual results differ from the company’s assumptions, ensuing actions might differ from those anticipated. You are therefore cautioned not to place undue reliance on such forward-looking statements which speak only as of the date hereof.
On Slide 3, you see the agenda for today’s
